The French multicentre study of ramipril in ambulatory patients with mild-to-moderate hypertension.
Identifieur interne : 000716 ( Main/Exploration ); précédent : 000715; suivant : 000717The French multicentre study of ramipril in ambulatory patients with mild-to-moderate hypertension.
Auteurs : A. Carré [France] ; F. Zannad ; D. VasmantSource :
- Clinical physiology and biochemistry [ 0252-1164 ] ; 1992.
Descripteurs français
- KwdFr :
- Adolescent (MeSH), Adulte (MeSH), Adulte d'âge moyen (MeSH), Association de médicaments (MeSH), Calendrier d'administration des médicaments (MeSH), Femelle (MeSH), France (MeSH), Furosémide (usage thérapeutique), Humains (MeSH), Hypertension artérielle (traitement médicamenteux), Mâle (MeSH), Méthode en double aveugle (MeSH), Méthode en simple aveugle (MeSH), Pression sanguine (effets des médicaments et des substances chimiques), Ramipril (administration et posologie), Ramipril (effets indésirables), Ramipril (usage thérapeutique), Sujet âgé (MeSH).
- MESH :
- administration et posologie : Ramipril.
- effets des médicaments et des substances chimiques : Pression sanguine.
- effets indésirables : Ramipril.
- traitement médicamenteux : Hypertension artérielle.
- usage thérapeutique : Furosémide, Ramipril.
- Adolescent, Adulte, Adulte d'âge moyen, Association de médicaments, Calendrier d'administration des médicaments, Femelle, France, Humains, Mâle, Méthode en double aveugle, Méthode en simple aveugle, Sujet âgé.
- Wicri :
- geographic : France.
English descriptors
- KwdEn :
- Adolescent (MeSH), Adult (MeSH), Aged (MeSH), Blood Pressure (drug effects), Double-Blind Method (MeSH), Drug Administration Schedule (MeSH), Drug Therapy, Combination (MeSH), Female (MeSH), France (MeSH), Furosemide (therapeutic use), Humans (MeSH), Hypertension (drug therapy), Male (MeSH), Middle Aged (MeSH), Ramipril (administration & dosage), Ramipril (adverse effects), Ramipril (therapeutic use), Single-Blind Method (MeSH).
- MESH :
- chemical , administration & dosage : Ramipril.
- chemical , adverse effects : Ramipril.
- chemical , therapeutic use : Furosemide, Ramipril.
- geographic : France.
- drug effects : Blood Pressure.
- drug therapy : Hypertension.
- Adolescent, Adult, Aged, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Single-Blind Method.
Abstract
The aim of this 16-week trial was to determine the safety and efficacy of a step-care regimen of ramipril, an angiotensin converting enzyme inhibitor, from the minimal active dose (2.5 mg) in patients treated for mild to moderate hypertension. The trial was conducted by 102 general practitioners in 770 patients with mild to moderate hypertension. After a response rate to a 4-week placebo therapy of 9.1%, 57.0% of patients given active treatment with ramipril responded to daily doses of 2.5 mg. Ramipril 5 mg daily was effective in 55.6% of the remaining patients. There was no apparent statistically significant difference between the treatments with ramipril 10 mg or a combination of ramipril 5 mg + Lasix 20 mg daily (44.7% and 47.4% response respectively) in a 6-week double-blind arm of the study. In total, more than 90% of patients responded to treatment with ramipril by the end of the study. The incidence of adverse events was generally low, such as headache, cough, dizziness, asthenia, cramps and nausea. The incidence of cough appeared to be related both to the dosage of ramipril given and to outbreaks of influenza syndrome. Thirty-eight patients discontinued active treatment as a result of minor events such as cough, dizziness or diarrhoea, and one case each of myalgia and papular rash. There were no significant variations in laboratory parameters during the study, especially fasting blood glucose and apolipoprotein A1 and B. The results of this study provide evidence of the safety and efficacy.(ABSTRACT TRUNCATED AT 250 WORDS)
PubMed: 1302160
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The French multicentre study of ramipril in ambulatory patients with mild-to-moderate hypertension.</title><author><name sortKey="Carre, A" sort="Carre, A" uniqKey="Carre A" first="A" last="Carré">A. Carré</name><affiliation wicri:level="3"><nlm:affiliation>Service de Médecine Interne et HTA, Hôpital Cardiologique, Lille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de Médecine Interne et HTA, Hôpital Cardiologique, Lille</wicri:regionArea><placeName><region type="region">Hauts-de-France</region><region type="old region">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Zannad, F" sort="Zannad, F" uniqKey="Zannad F" first="F" last="Zannad">F. Zannad</name></author><author><name sortKey="Vasmant, D" sort="Vasmant, D" uniqKey="Vasmant D" first="D" last="Vasmant">D. Vasmant</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1992">1992</date><idno type="RBID">pubmed:1302160</idno><idno type="pmid">1302160</idno><idno type="wicri:Area/Main/Corpus">000720</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000720</idno><idno type="wicri:Area/Main/Curation">000720</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000720</idno><idno type="wicri:Area/Main/Exploration">000720</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The French multicentre study of ramipril in ambulatory patients with mild-to-moderate hypertension.</title><author><name sortKey="Carre, A" sort="Carre, A" uniqKey="Carre A" first="A" last="Carré">A. Carré</name><affiliation wicri:level="3"><nlm:affiliation>Service de Médecine Interne et HTA, Hôpital Cardiologique, Lille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de Médecine Interne et HTA, Hôpital Cardiologique, Lille</wicri:regionArea><placeName><region type="region">Hauts-de-France</region><region type="old region">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Zannad, F" sort="Zannad, F" uniqKey="Zannad F" first="F" last="Zannad">F. Zannad</name></author><author><name sortKey="Vasmant, D" sort="Vasmant, D" uniqKey="Vasmant D" first="D" last="Vasmant">D. Vasmant</name></author></analytic><series><title level="j">Clinical physiology and biochemistry</title><idno type="ISSN">0252-1164</idno><imprint><date when="1992" type="published">1992</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent (MeSH)</term><term>Adult (MeSH)</term><term>Aged (MeSH)</term><term>Blood Pressure (drug effects)</term><term>Double-Blind Method (MeSH)</term><term>Drug Administration Schedule (MeSH)</term><term>Drug Therapy, Combination (MeSH)</term><term>Female (MeSH)</term><term>France (MeSH)</term><term>Furosemide (therapeutic use)</term><term>Humans (MeSH)</term><term>Hypertension (drug therapy)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Ramipril (administration & dosage)</term><term>Ramipril (adverse effects)</term><term>Ramipril (therapeutic use)</term><term>Single-Blind Method (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent (MeSH)</term><term>Adulte (MeSH)</term><term>Adulte d'âge moyen (MeSH)</term><term>Association de médicaments (MeSH)</term><term>Calendrier d'administration des médicaments (MeSH)</term><term>Femelle (MeSH)</term><term>France (MeSH)</term><term>Furosémide (usage thérapeutique)</term><term>Humains (MeSH)</term><term>Hypertension artérielle (traitement médicamenteux)</term><term>Mâle (MeSH)</term><term>Méthode en double aveugle (MeSH)</term><term>Méthode en simple aveugle (MeSH)</term><term>Pression sanguine (effets des médicaments et des substances chimiques)</term><term>Ramipril (administration et posologie)</term><term>Ramipril (effets indésirables)</term><term>Ramipril (usage thérapeutique)</term><term>Sujet âgé (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Ramipril</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Ramipril</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Furosemide</term><term>Ramipril</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>France</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Ramipril</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Blood Pressure</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hypertension</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Pression sanguine</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Ramipril</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Hypertension artérielle</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Furosémide</term><term>Ramipril</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Double-Blind Method</term><term>Drug Administration Schedule</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Single-Blind Method</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Association de médicaments</term><term>Calendrier d'administration des médicaments</term><term>Femelle</term><term>France</term><term>Humains</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Méthode en simple aveugle</term><term>Sujet âgé</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>France</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The aim of this 16-week trial was to determine the safety and efficacy of a step-care regimen of ramipril, an angiotensin converting enzyme inhibitor, from the minimal active dose (2.5 mg) in patients treated for mild to moderate hypertension. The trial was conducted by 102 general practitioners in 770 patients with mild to moderate hypertension. After a response rate to a 4-week placebo therapy of 9.1%, 57.0% of patients given active treatment with ramipril responded to daily doses of 2.5 mg. Ramipril 5 mg daily was effective in 55.6% of the remaining patients. There was no apparent statistically significant difference between the treatments with ramipril 10 mg or a combination of ramipril 5 mg + Lasix 20 mg daily (44.7% and 47.4% response respectively) in a 6-week double-blind arm of the study. In total, more than 90% of patients responded to treatment with ramipril by the end of the study. The incidence of adverse events was generally low, such as headache, cough, dizziness, asthenia, cramps and nausea. The incidence of cough appeared to be related both to the dosage of ramipril given and to outbreaks of influenza syndrome. Thirty-eight patients discontinued active treatment as a result of minor events such as cough, dizziness or diarrhoea, and one case each of myalgia and papular rash. There were no significant variations in laboratory parameters during the study, especially fasting blood glucose and apolipoprotein A1 and B. The results of this study provide evidence of the safety and efficacy.(ABSTRACT TRUNCATED AT 250 WORDS)</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1302160</PMID><DateCompleted><Year>1993</Year><Month>06</Month><Day>10</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0252-1164</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>3</Issue><PubDate><Year>1992</Year></PubDate></JournalIssue><Title>Clinical physiology and biochemistry</Title><ISOAbbreviation>Clin Physiol Biochem</ISOAbbreviation></Journal><ArticleTitle>The French multicentre study of ramipril in ambulatory patients with mild-to-moderate hypertension.</ArticleTitle><Pagination><MedlinePgn>105-12</MedlinePgn></Pagination><Abstract><AbstractText>The aim of this 16-week trial was to determine the safety and efficacy of a step-care regimen of ramipril, an angiotensin converting enzyme inhibitor, from the minimal active dose (2.5 mg) in patients treated for mild to moderate hypertension. The trial was conducted by 102 general practitioners in 770 patients with mild to moderate hypertension. After a response rate to a 4-week placebo therapy of 9.1%, 57.0% of patients given active treatment with ramipril responded to daily doses of 2.5 mg. Ramipril 5 mg daily was effective in 55.6% of the remaining patients. There was no apparent statistically significant difference between the treatments with ramipril 10 mg or a combination of ramipril 5 mg + Lasix 20 mg daily (44.7% and 47.4% response respectively) in a 6-week double-blind arm of the study. In total, more than 90% of patients responded to treatment with ramipril by the end of the study. The incidence of adverse events was generally low, such as headache, cough, dizziness, asthenia, cramps and nausea. The incidence of cough appeared to be related both to the dosage of ramipril given and to outbreaks of influenza syndrome. Thirty-eight patients discontinued active treatment as a result of minor events such as cough, dizziness or diarrhoea, and one case each of myalgia and papular rash. There were no significant variations in laboratory parameters during the study, especially fasting blood glucose and apolipoprotein A1 and B. The results of this study provide evidence of the safety and efficacy.(ABSTRACT TRUNCATED AT 250 WORDS)</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Carré</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Service de Médecine Interne et HTA, Hôpital Cardiologique, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zannad</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Vasmant</LastName><ForeName>D</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D018848">Controlled Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Clin Physiol Biochem</MedlineTA><NlmUniqueID>8305885</NlmUniqueID><ISSNLinking>0252-1164</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>7LXU5N7ZO5</RegistryNumber><NameOfSubstance UI="D005665">Furosemide</NameOfSubstance></Chemical><Chemical><RegistryNumber>L35JN3I7SJ</RegistryNumber><NameOfSubstance UI="D017257">Ramipril</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005665" MajorTopicYN="N">Furosemide</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017257" MajorTopicYN="N">Ramipril</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016037" MajorTopicYN="N">Single-Blind Method</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1992</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1992</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1992</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1302160</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Hauts-de-France</li><li>Nord-Pas-de-Calais</li></region><settlement><li>Lille</li></settlement></list><tree><noCountry><name sortKey="Vasmant, D" sort="Vasmant, D" uniqKey="Vasmant D" first="D" last="Vasmant">D. Vasmant</name><name sortKey="Zannad, F" sort="Zannad, F" uniqKey="Zannad F" first="F" last="Zannad">F. Zannad</name></noCountry><country name="France"><region name="Hauts-de-France"><name sortKey="Carre, A" sort="Carre, A" uniqKey="Carre A" first="A" last="Carré">A. Carré</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000716 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000716 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:1302160
|texte= The French multicentre study of ramipril in ambulatory patients with mild-to-moderate hypertension.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:1302160" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeFranceV1
| This area was generated with Dilib version V0.6.35. |  |